59124 Federal Register / Vol. 71, No. 194 / Friday, October 6, 2006 / Notices 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute on Deafness and 

Other Communication Disorders, 

Notice of Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. Appendix 2), notice 

is hereby given of the following 

meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute on 

Deafness and Other Communication 

Disorders Special Emphasis Panel, CDRC 

Training Conflict. 

Date: October 12, 2006. 

Time: 8 a.m. to 8:30 a.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Wyndham Washington, DC, 1400 M 

Street, NW., Washington, DC 20005. 

Contact Person: Christine A. Livingston, 

Scientific Review Administrator, Division of 

Extramural Activities, National Institutes of 

Health/NIDCD, 6120 Executive Blvd.—MSC 

7180, Bethesda, MD 20892, (301) 496–8683, 

livingsc@mail.nih.gov. 

This notice is being published less than 15 

days prior to the meeting due to the timing 

limitations imposed by the review and 

funding cycle. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.173, Biological Research 

Related to Deafness and Communicative 

Disorders, National Institutes of Health, HHS) 

Dated: September 29, 2006. 

Anna Snouffer, 

Acting Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 06–8521 Filed 10–5–06; 8:45 am] 

BILLING CODE 4140–01–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Office of Biotechnology Activities, 

Office of Science Policy, Office of the 

Director; Notice of Meeting 

Pursuant to section 10(a) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. Appendix 2), notice 

is hereby given of the sixth meeting of 

the National Science Advisory Board for 

Biosecurity (NSABB). 

Under authority 42 U.S.C. 217a, 

Section 222 of the Public Health Service 

Act, as amended, the Department of 

Health and Human Services established 

NSABB to provide advice, guidance and 

leadership regarding Federal oversight 

of dual-use research, defined as 

biological research with legitimate 

scientific proposes that could be 

misused to pose a biological threat to 

public health and/or national security. 

The meeting will be open to the 

public; however, pre-registration is 

strongly recommended due to space 

limitations. Persons planning to attend 

should register online at http:// 

www.biosecurityboard.gov/meetings.asp 

or by calling Capital Consulting 

Corporation (Contact: Saundra M. 

Bromberg) at 301–468–6004, ext. 406. 

Individuals who plan to attend and 

need special assistance, such as sign 

language interpretation or other 

reasonable accommodations, should 

indicate these requirements upon 

registration. 

Name of Committee: National Science 

Advisory Board for Biosecurity. 

Date: October 25, 2006. 

Open: 12 p.m to 5 p.m. 

Agenda: Presentations and discussions 

regarding: (1) Draft recommendations of the 

NSABB Working Group on Synthetic 

Genomics for addressing biosecurity 

concerns raised by the ability to synthesize 

select agents de novo; (2) draft statement by 

the Communications Working Group on the 

necessity of open scientific communication; 

(3) public comments; and (4) other business 

of the Board. 

Place: The National Institutes of Health, 31 

Center Drive, Building 31, 6C—Room 10, 

Bethesda, Maryland 20892. 

Contact Persons: Laurie Lewallen, NSABB 

Program Assistant, NIH Office of 

Biotechnology Activities, 6705 Rockledge 

Drive, Bethesda, Maryland 20892. (301) 496–

9838. 

This meeting will also be webcast. The 

draft meeting agenda and other information 

about NSABB, including information about 

access to the webcast and pre-registration, 

will be available at http:// 

www.biosecurityboard.gov/meetings.asp. 

Any member of the public interested in 

presenting oral comments at the meeting may 

notify the Contact Person listed on this notice 

at least 10 days in advance of the meeting. 

Interested individuals and representatives of 

an organization may submit a letter of intent, 

a brief description of the organization 

represented and a short description of the 

oral presentation. Only one representative of 

an organization may be allowed to present 

oral comments. Both printed and electronic 

copies are requested for the record. In 

addition, any interested person may file 

written comments with the committee. All 

written comments must be received by 

October 16, 2006 and should be sent via email to nsabb@od.nih.gov with ‘‘NSABB 

Public Comment’’ as the subject line or by 

regular mail to 6705 Rockledge Drive, Suite 

750, Bethesda, MD 20892, Attention Laurie 

Lewallen. The statement should include the 

name, address, telephone number and, when 

applicable, the business or professional 

affiliation of the interested person. 

In the interest of security, NIH has 

instituted stringent procedures for entrance 

onto NIH campus. All visitor vehicles, 

including taxicabs, hotel, and airport shuttles 

will be inspected before being allowed on 

Campus. Visitors will be asked to show one 

form of identification (for example, a 

government-issued photo ID, driver’s license, 

or passport) and to state the purpose of their 

visit. 

Dated: September 29, 2006. 

Anna Snouffer, 

Acting Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 06–8519 Filed 10–5–06; 8:45 am] 

BILLING CODE 4140–01–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Center for Scientific Review; Notice of 

Closed Meetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. Appendix 2), notice 

is hereby given of the following 

meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in section 552b(c)(4) 

and 552b(c)(6), Title 5 U.S.C., as 

amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel, 

Reproductive Endocrinology. 

Date: October 6, 2006. 

Time: 11 a.m. to 1 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6701 

Rockledge Drive, Bethesda, MD 20892, 

(Telephone Conference Call). 

Contact Person: Krish Krishnan, PhD, 

Scientific Review Administrator, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 6164, 

MSC 7892, Bethesda, MD 20892, (301) 435–

1041, krishnak@csr.nih.gov. 

This notice is being published less than 15 

days prior to the meeting due to the timing 

limitations imposed by the review and 

funding cycle. 


cprice-sewell on PROD1PC66 with NOTICES
Federal Register / Vol. 71, No. 194 / Friday, October 6, 2006 / Notices 59125 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel, T Cell/B 

Cell Mechanisms. 

Date: October 17, 2006. 

Time: 1 p.m. to 2:30 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6701 

Rockledge Drive, Bethesda, MD 20892, 

(Telephone Conference Call). 

Contact Person: Calbert A. Laing, PhD, 

Scientific Review Administrator, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 4210, 

MSC 7812, Bethesda, MD 20892, 301–435–

1221, laingc@csr.nih.gov. 

This notice is being published less than 15 

days prior to the meeting due to the timing 

limitations imposed by the review and 

funding cycle. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel, Cognition 

and Perception SRA Conflict Review. 

Date: October 27, 2006. 

Time: 8:30 a.m. to 10:30 a.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Hotel Helix, 1430 Rhode Island 

Ave., NW., Washington, DC 20005. 

Contact Person: Dana Jeffrey Plude, PhD, 

Scientific Review Administrator, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 3192, 

MSC 7848, Bethesda, MD 20892, 301–435–

2309, pluded@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel, Non-HIV 

Microbial Vaccine Development. 

Date: October 30, 2006. 

Time: 8 a.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: The Watergate, 2650 Virginia 

Avenue, NW., Washington, DC 20037. 

Contact Person: Jin Huang, PhD, Scientific 

Review Administrator, Center for Scientific 

Review, National Institutes of Health, 6701 

Rockledge Drive, Room 4095G, MSC 7812, 

Bethesda, MD 20892, 301–435–1187, 

jh377p@nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel, Radiation 

Therapy and Biology SBIR/STTR. 

Date: October 30–31, 2006. 

Time: 8:30 a.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6701 

Rockledge Drive, Bethesda, MD 20892, 

(Virtual Meeting). 

Contact Person: Bo Hong, PhD, Scientific 

Review Administrator, Center for Scientific 

Review, National Institutes of Health, 6701 

Rockledge Drive, Room 6194, MSC 7804, 

Bethesda, MD 20892, 301–435–5879, 

hongb@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel, ZRG1 ONC–

P (03): Cancer Chemoprevention. 

Date: October 30, 2006. 

Time: 4 p.m. to 6 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6701 

Rockledge Drive, Bethesda, MD 20892, 

(Telephone Conference Call). 

Contact Person: Zhiqiang Zou, MD, PhD, 

Scientific Review Administrator, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 6190, 

MSC 7804, Bethesda, MD 20892, 301–451–

0132, zouzhiq@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel, NIDDK PAR 

06 113. 

Date: October 31–November 1, 2006. 

Time: 8 a.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6701 

Rockledge Drive, Bethesda, MD 20892, 

(Virtual Meeting). 

Contact Person: Daniel F. McDonald, PhD, 

Scientific Review Administrator, Chief, Renal 

and Urological Sciences IRG, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 4214, 

MSC 7814, Bethesda, MD 20892, (301) 435–

1215, mcdonald@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel, Molecular, 

Cellular and Developmental Neurobiological 

Small Business Applications. 

Date: October 31, 2006. 

Time: 8:30 a.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Jurys Washington Hotel, 1500 New 

Hampshire Avenue, NW., Washington, DC 

20036. 

Contact Person: Michael A. Lang, PhD, 

Scientific Review Administrator, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 4140, 

MSC 7850, Bethesda, MD 20892, (301) 435–

1265, langm@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel, Member 

Conflicts in Biobehavioral Regulation and 

Learning. 

Date: October 31, 2006. 

Time: 12 p.m. to 2 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6701 

Rockledge Drive, Bethesda, MD 20892, 

(Telephone Conference Call). 

Contact Person: Jane A. DoussardRoosevelt, PhD, Scientific Review 

Administrator, Center for Scientific Review, 

National Institutes of Health, 6701 Rockledge 

Drive, Room 3184, MSC 7848, Bethesda, MD 

20892, (301) 435–4445, doussarj@csr.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.306, Comparative Medicine; 

93.333, Clinical Research, 93.306, 93.333, 

93.337, 93.393–93.396, 93.837–93.844, 

93.846–93.878, 93.892,93.893, National 

Institutes of Health, HHS) 

Dated: September 28, 2006. 

Anna Snouffer, 

Acting Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 06–8516 Filed 10–5–06; 8:45 am] 

BILLING CODE 4140–01–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Center for Scientific Review; Amended 

Notice of Meeting 

Notice is hereby given of a change in 

the meeting of the Drug Discovery and 

Molecular Pharmacology Study Section, 

October 5, 2006, 8 a.m. to October 6, 

2006, 5 p.m., Wyndham City Center 

Hotel, 1143 New Hampshire Ave., NW., 

Washington, DC 20037 which was 

published in the Federal Register on 

September 15, 2006, 71 FR 54511–

54512. 

The meeting will be held at the Red 

Lion Hotel on Fifth Avenue, 1415 Fifth 

Avenue, Seattle, WA 98101. The 

meeting dates and time remain the 

same. The meeting is closed to the 

public. 

Dated: September 28, 2006. 

Anna Snouffer, 

Acting Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 06–8517 Filed 10–5–06; 8:45 am] 

BILLING CODE 4140–01–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Prospective Grant of an Exclusive 

License: Development and 

Commercialization of Therapeutic 

Products for Autoimmune Diseases 

Including Rheumatoid Arthritis (RA), 

Inflammatory Bowel Disease (IBD) and 

Psoriasis 

AGENCY: National Institutes of Health, 

Public Health Service, HHS. 

ACTION: Notice. 

SUMMARY: This notice, in accordance 

with 35 U.S.C. 209(c)(1) and 37 CFR 

404.7(a)(1)(i), announces that the 

Department of Health and Human 

Services is contemplating the grant of an 

exclusive license to practice the 

inventions embodied in United States 

Patent Application Number 60/181,909 

entitled ‘‘Identification of a Novel 

Domain in the Tumor Necrosis Factor 

Receptor Family that Mediates Preligand Receptor Assembly and 

Function’’ filed February 11, 2000 (HHS 

Ref. No. E–095–2000/0–US–01); U.S. 

Patent Application No. PCT/US01/ 

04125 entitled ‘‘Identification of a Novel 

Domain in the Tumor Necrosis Factor 

Receptor Family that Mediates Preligand Receptor Assembly and 

Function’’ filed February 9, 2001, 2000 

(HHS Ref. No. E–095–2000/0–PCT–02); 


cprice-sewell on PROD1PC66 with NOTICES